Clinical Trial Update: Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old

View source ↗

Summary

A clinical trial is recruiting to evaluate the efficacy and safety of Reamberin for pathogenetic therapy of viral enteric infection in children aged 1-6 years.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Viral Gastroenteritis

Drugs mentioned

• Reamberin

Snippet

Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company | Conditions: Viral Enteric Infection | Status: RECRUITING